Introducing a new era of Alzheimer’s care

Learn more

A new approach to managing agitation and related symptoms — helping patients live more peacefully at home, surrounded by those who matter most.

Background dots
Our Mission

We are developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms including agitation in patients with Alzheimer’s disease dementia.

Our Science

With our novel drug Deraphan, we are advancing a dual-mechanism approach that has the potential to affect key neurological pathways to reduce agitation, psychosis, and mood-related symptoms in dementia

Dextromethorphan

Calms brain overactivity by blocking NMDA receptors

Has been used safely in medicine for over 60 years.

Deramciclane

Slows degradation of Dextromethorphan by inhibiting CYP2D6 in the liver

Blocks 5-HT2A/2C receptors which may have impact on several neuropsychiatric symptoms

No safety concerns identified in >2,500 subjects tested exposed to Deramciclane for up to 1 year

Safe &
tolerable

Non-toxic
profile

Long-term
usability

Patient-centered
outcomes

Learn More
Who we Serve

Beyond symptom relief, toward meaningful gains in patient quality of life

  • Patients
  • Families and caregivers
  • Healthcare professionals
  • Pharmaceutical partners
Clinical Trials

The SERENADA study

(Serenity in Alzheimer’s Disease Agitation) is Exciva’s clinical Phase 2/3 study

Find out whether participation in this trial might be right for you or your loved one

Find out more
News

The latest at Exciva

Explore all news

A better future for Alzheimer’s patients

An approach centered on de-escalation rather than suppression, patient wellbeing rather than behavioral control, and sustained outcomes rather than temporary relief.

Find out more